US · Healthcare · Biotechnology
EPS came in at -1.06 against a street estimate of -1.13 — a beat of 6.2%.
Analysts rate Apogee Therapeutics, Inc. Common Stock a strong buy (9 buy, 0 hold, 0 sell out of 9) with an average price target of $130.53.
| Fund | Stake |
|---|---|
| T. Rowe Price Investment Management,Inc. | 13.62% |
| FMR Inc | 12.25% |
| VR Adviser, LLC | 11.23% |
| Wellington Management Company LLP | 5.79% |
| BlackRock Inc | 5.40% |
| RTW INVESTMENTS, LLC | 3.68% |
| Vanguard Capital Management, LLC | 3.31% |
| HHG PLC | 3.12% |
| Document | Date |
|---|---|
| Material agreement · Q2 2026 | 2026-06-22 |
| Material agreement · Q2 2026 | 2026-06-22 |
| Shareholder vote results · Q2 2026 | 2026-06-12 |
| Material agreement · Q2 2026 | 2026-05-27 |
| Quarterly report · Q1 2026 | 2026-05-11 |
| Proxy statement · Q2 2026 | 2026-04-24 |
| Annual report FY2025 | 2026-03-02 |
| Quarterly report · Q3 2025 | 2025-11-10 |
Readable in the app.
| Announcement | Date |
|---|---|
| Entered into antibody discovery agreement with Paragon Therapeutics for IL-31R Apogee Therapeutics entered into two agreements with Paragon Therapeutics on June 17, 2026 to develop antibody treatments targeting IL-31R (interleukin 31 receptor), a protein involved in in | 2026-06-22 |
| Merger agreement executed with AbbVie; voting agreement with stockholders signed AbbVie is acquiring Apogee Therapeutics, a biopharmaceutical company. This 8-K filing announces that major Apogee stockholders (including venture capital firms Venrock Healthcare Capital Par | 2026-06-22 |
| Revenue participation rights agreement with Blackstone Life Sciences for drug funding Apogee Therapeutics secured a major non-dilutive funding deal with Blackstone Life Sciences worth up to $950 million. The company will receive $100 million upfront, with three additional mil | 2026-05-27 |
| Four clinical data readouts anticipated in 2026; cash runway extended to H2 2028 Apogee Therapeutics, a clinical-stage biotech company, announced strong progress on its drug pipeline and completed a $345 million funding round. The company's lead drug APG777, an IL-13 tar | 2025-11-10 |
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Apogee Therapeutics, Inc. Common Stock — free to start.
Google PlayApp StoreData updated 2026-08-05.